Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo

Galeterone (Gal) is a first-in-class multi-target oral small molecule that will soon enter pivotal phase III clinical trials in castration resistant prostate cancer (CRPC) patients. Gal disrupts androgen receptor (AR) signaling via inhibition of CYP17, AR antagonism and AR degradation. Resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwegyir-Afful, Andrew K., Ramalingam, Senthilmurugan, Purushottamachar, Puranik, Ramamurthy, Vidya P., Njar, Vincent C.O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695001/
https://www.ncbi.nlm.nih.gov/pubmed/26196320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695001/
https://www.ncbi.nlm.nih.gov/pubmed/26196320

Ejemplares similares